Device Trial Radar · NCT06604884
NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Dec 12, 2025
Primary completion
Aug 2029
Study completion Sep 2033
Sponsor
- Lead sponsor
- Medtronic Neurovascular Clinical AffairsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Sep 20, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
Summary
As written by the sponsor on the registry.
The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shield Technology™ ("Pipeline™ Vantage Device") in a post approval setting.
Conditions
- Intracranial Aneurysm
Interventions
Treatment of Intracranial AneurysmsDevice
Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of the composite outcome (Occlusion of the target aneurysm, Significant parent artery stenosis, Retreatment of the target aneurysm) at 1 year post-procedure.Time frame: 1 Year
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Baptist Medical Center Jacksonville
Jacksonville, Florida · Recruiting
Wellstar Research Institute
Marietta, Georgia · Recruiting
Endeavor Health
Evanston, Illinois · Recruiting
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.